ArticleGlomerular diseases
Membranoproliferative Glomerulonephritis due to
Article in Glomerular diseases. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Membranoproliferative glomerulonephritis (MPGN) is a rare pattern of glomerular injury that may be immune complex-mediated (ICM), most often secondary to infections, autoimmune disorders, or hematologic or less often solid tumor malignancies. Infections with Case Presentation: The patient is a 44-year-old male with alcoholic cirrhosis who presented with hematuria, proteinuria, and acute kidney injury (AKI), with negative blood cultures. Kidney biopsy revealed ICM-MPGN, with no underlying etiology identified. His clinical course was complicated by recurrent fluid overload with AKI requiring dialysis. Following corticosteroid therapy for ICM-MPGN, he developed Conclusion: This case highlights the role of HACEK organisms causing subclinical and difficult to diagnose IE, the increased risk of infection in patients with cirrhosis, and the need for a thorough evaluation for infectious etiologies in patients with ICM-MPGN prior to immunosuppressive therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.